Ajanta Pharma (AJP) delivered in-line sales in 4QFY24. However, EBITDA/PATcame in lower than our expectations, due to higher opex and higher taxoutgo. AJP continued to outperform the industry in domestic formulation(DF) and Asia market. The performance is expected to improve in the Africabranded generics market going forward.